Biologics that inhibit the Th17 pathway and related cytokines to treat inflammatory disorders.

Abstract

INTRODUCTION:

Advances in the understanding of TNF-α and IL-17 synergistic functions have recently led to the concept that patients who do not respond or who respond inadequately to TNF-α inhibitors may have IL-17-driven diseases, opening up the way for a new class of therapeutic development: Th17-inhibitors. Areas covered: In this review, the authors discuss the central role that the IL-23/Th17 axis plays in the pathogenesis of several inflammatory diseases, such as psoriasis, highlighting its position as a relevant therapeutic target. In particular, the authors start by giving a brief historical excursus on biologic agent development up until the success of TNF-α inhibitors, and continue with an overview of IL12/23 pathway inhibition. Next, they describe Th17 cell biology, focusing on the role of IL-17 in host defense and in human immune-inflammatory diseases, discussing the use and side effects of IL-17 inhibitors. Expert opinion: The IL-23/Th17 signaling pathway plays a central role in the pathogenesis of several inflammatory diseases, such as psoriasis. Recent data has demonstrated that biologics neutralizing IL-17 (ixekizumab, secukinumab) or its receptor (brodalumab) are highly effective with a positive safety profile in treating moderate to severe psoriasis, offering new treatment possibilities, especially for patients who do not respond adequately to anti-TNF-α therapies.

• Authors: Anna Balato, Emanuele Scala, Nicola Balato, Giuseppina Caiazzo, Roberta Di Caprio, Giuseppe Monfrecola, Annunziata Raimondo, Serena Lembo, Fabio Ayala
• Journal: Expert opinion on biological therapy (Expert Opin Biol Ther) Vol. 17 Issue 11 Pg. 1363-1374 (11 2017) ISSN: 1744-7682 [Electronic] England
• PMID: 28791896 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Biological Products
• Cytokines
• Interleukin-17
• brodalumab
• ixekizumab
• secukinumab

Topics

• Antibodies, Monoclonal (pharmacology, therapeutic use)
• Antibodies, Monoclonal, Humanized (pharmacology, therapeutic use)
• Biological Products (pharmacology, therapeutic use)
• Cytokines (antagonists & inhibitors, immunology, metabolism)
• Humans
• Interleukin-17 (antagonists & inhibitors, immunology, metabolism)
• Psoriasis (drug therapy)
• Signal Transduction (drug effects)
• Th17 Cells (drug effects, immunology, metabolism)